T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY

Pfizer Inc(PFE)

May 17, 2006
Near 4% yield which is very attractive. Good level to buy. Trading at about 12 X earnings. Gives about 35% return on equity. No debt.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$24.27

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 10, 2006
His model price is $38, a 49% positive differential. Pays a nice fat dividend.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.04

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 09, 2006
Has an ace dividend yield of about 3%. Turning things around. Have a good pipeline. Has there consumer products operation up for sale but thinks they will spin it out to the shareholders. Very little downside risk.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.51

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 27, 2006
Owns Teva (TEVA-Q) as a growth stock and owns this one as a value stock. This one seems to be doing things correctly, more so than Merk (MRK-N). Feels the environment has bottomed out and will be getting better. Low risk.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.86

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 30, 2006
Likes the pharmaceutical sector. This one is very cheap. Dividend of 3.5%. Trading at 10 X earnings.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$25.20

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 21, 2006
The fundamental outlook is improving. The worst is behind it. The company is swimming in cash. There could be another dividend increase.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.31

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 15, 2006
Pfizer is a large cap pharma. Probably the largest pharma company in the world. Has suffered along with the rest of the industry. It is well positioned. Very attractive. Good dividend yield. Predicts it will continue to grow 12-15%.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$25.95

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Pfizer Inc(PFE)

Feb 28, 2006
Developed a new inhalant insulin product. Good product as diabetes continue to grow. They have had some litigation problems and some patents will be expiring. Worth watching it.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$26.19

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
TRADE

Pfizer Inc(PFE)

Feb 24, 2006
They need to do some building of pipeline, so the stock will be going sideways for awhile, but there will be demand.
Photo of David DriscollDavid DriscollUnlock Rating
$26.14

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2006
He likes this industry. The growth is not what it used to be. Evaluations are cheaper than they have been in a long time. Growth stocks are cheaper than they have been in last 20 years.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$26.19

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 14, 2006
It's in their top 10 of their US-value 50. It's currently below what he paid for it.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$25.50

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 13, 2006
(A Top Pick Dec 5/05. Up 20%.) They got a positive legal ruling on Lipator which protects their patent. They increased their dividend. Have just announced that they will be doing something with their consumer product division, spinning out to shareholders or selling it.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$25.58

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 02, 2006
This is a value stock and is showing up under his parameters as a buy. As a strategic investor, this would be the time to buy this.
Photo of Jim O'ShaughnessyJim O'Shaughnessy
Owned
Unlock Rating
$25.78

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 31, 2006
Thinks the heyday of those large pharmaceutical companies have come and gone. The pipeline is relatively bare. They have reached a point in time when they are trying to cut costs at a greater rate than the revenue decline. Not a good business to be in at this point.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$25.68

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 20, 2006
4% dividend yield. Trades had about 11 X earnings. They should continue to do well.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.71

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 631 to 645 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like